LYMPHOMA, LARGE-CELL, ANAPLASTIC
Clinical trials for LYMPHOMA, LARGE-CELL, ANAPLASTIC explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, LARGE-CELL, ANAPLASTIC trials appear
Sign up with your email to follow new studies for LYMPHOMA, LARGE-CELL, ANAPLASTIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental lymphoma drug enters first human tests
Disease control TerminatedThis early-stage study tested an experimental drug called PF-08046044/SGN-35C in 58 adults with advanced lymphomas (Hodgkin and non-Hodgkin types) who had no standard treatment options left. The main goals were to check safety, find the best dose, and see how the body handles the…
Matched conditions: LYMPHOMA, LARGE-CELL, ANAPLASTIC
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 17, 2026 10:44 UTC
-
New lymphoma drug trial halted early after safety check
Disease control TerminatedThis early-stage study tested a new drug, PF-08046045, in 22 adults with advanced lymphomas that had not responded to other treatments. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
Matched conditions: LYMPHOMA, LARGE-CELL, ANAPLASTIC
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 14, 2026 12:06 UTC